We develop skin-targeted LNPs through skin-selective lipid engineering, surface ligand functionalization, and delivery-format adaptation, providing end-to-end support from design and synthesis to formulation, characterization, and skin-model evaluation.
Skin-targeted LNPs are engineered to deliver nucleic acids and other payloads into defined skin compartments—the viable epidermis, the dermis, and the hair follicle-associated niches—while avoiding the liver tropism that dominates conventional formulations. Because the stratum corneum blocks intact nanoparticles, and because keratinocytes, dermal fibroblasts, and melanocytes respond very differently to the same lipid chemistry, skin delivery demands formulation logic built around barrier penetration, cell-type selectivity, and compatibility with topical vehicles, injectable buffers, and device-based formats such as microneedle patches and hydrogels.
BOC Sciences provides integrated targeted LNP development, covering ionizable lipid design and screening, skin-targeting ligand synthesis, surface functionalization, payload encapsulation, topical-vehicle and device-format adaptation, and cellular and in vivo evaluation in skin-relevant models. We support customized LNPs for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing research, with the development scope matched to the intended skin compartment, target cell population, and administration route.
Skin-Targeted Lipid Nanoparticle IllustrationOur development services combine lipid chemistry, surface engineering, nanoparticle formulation, and skin-relevant biological evaluation. Projects can start with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective such as "express this payload in basal keratinocytes" or "silence this gene in dermal fibroblasts." We customize the development scope according to payload properties, target-cell characteristics, and the intended route of skin administration.
We investigate how ionizable lipid structures and supporting lipid components govern interactions with skin cells, intracellular payload release, and delivery depth within skin tissue.
We develop ligand-functionalized LNPs to bias uptake toward selected skin cell populations. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together, because the same ligand can improve binding yet reduce penetration if displayed incorrectly.
We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy matched to the intended skin-delivery route and format.
We evaluate candidate LNPs across particle attributes, skin-cell delivery, and tissue-level performance, so that formulation changes can be interpreted against functional payload delivery rather than size data alone.
Skin-targeted LNPs can be developed through lipid-intrinsic selectivity, surface display of skin-active ligands, or stimuli-responsive and penetration-enabled designs. BOC Sciences supports lipid design and synthesis, ligand modification, LNP formulation, and delivery evaluation. The following strategies provide different starting points depending on the target cell, the payload, and the administration route.
Skin delivery can be improved by tuning ionizable lipid pKa, headgroup structure, and helper lipid identity rather than adding a targeting ligand. Because keratinocytes, fibroblasts, and melanocytes endocytose and process LNPs differently, the same formulation can express strongly in one cell type and weakly in another.
Research reference: Ionizable lipid pKa tuning for in situ gene editing in human skin, including correction of a TGM1 disease mutation in ichthyosis patient cells (ACS Nano, 2023).
Hyaluronic acid (HA) decoration gives LNPs a skin-affinitive surface: HA engages CD44 on keratinocytes, fibroblasts, and many tumor cells, improves residence on the skin surface, and can replace conventional PEG shielding. HA-lipid conjugates are integrated during particle self-assembly so that the targeting layer and the stabilizing layer are the same component.
Research reference: HA-conjugated LNPs delivering PTEN mRNA by topical application, with deep skin penetration and CD44-selective tumor cell expression (Journal of Controlled Release, 2025).
Peptide and protein ligands provide the finest resolution of cell targeting within skin: cell-penetrating motifs support epidermal uptake, lectin-type ligands such as mannose-bearing constructs address skin-resident antigen-presenting cells, and antibody fragments can be directed toward markers with confirmed extracellular accessibility.
Research reference: Langerin-directed glycomimetic ligand-functionalized LNPs achieving selective mRNA delivery to skin-resident Langerhans cells with minimal off-target uptake (bioRxiv, 2025).
Topical skin delivery benefits from surfaces that change behavior after contact with skin: charge-switchable designs reduce nonspecific adhesion after penetration, ROS-responsive components neutralize oxidative stress in inflamed skin while releasing payload, and reducible or enzyme-cleavable anchors release ligands once uptake has occurred.
Research reference: A lipoic acid-derived ionizable lipid library enabling transdermal Cas9 mRNA/sgRNA delivery and CD93 genome editing in a murine psoriasis model (Journal of the American Chemical Society, 2025).
Share your payload, target skin compartment, and administration route. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and develop a comparative formulation strategy.
BOC Sciences develops skin-targeted LNPs for the payload classes most frequently used in cutaneous delivery research. Each payload requires a matched loading strategy, particle design, administration route, and functional readout, and we help connect skin-targeting design with payload-specific formulation requirements.
| Payload Type | Supported Uses, Delivery Routes & Skin-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Skin-Targeted LNP for mRNA | Designed for reporter expression, protein-replacement research, and growth-factor expression in epidermal and dermal cells. Route options include intradermal injection, microneedle-assisted delivery, and penetration-enabled topical application. Development focuses on mRNA integrity, encapsulation efficiency, layer-specific expression, and skin-versus-liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Skin-Targeted LNP for siRNA | Suitable for gene-knockdown studies in keratinocytes, dermal fibroblasts, and melanocyte-associated models, including pathways involved in inflammation, fibrosis, and pigmentation. Route options include intradermal injection and topical delivery with charge- or size-optimized designs. Development evaluates knockdown depth, cell-type selectivity, and skin retention, drawing on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| Skin-Targeted LNP for miRNA | Applicable to pigmentation, barrier-function, and differentiation research where regulatory miRNAs modulate melanocyte and keratinocyte programs. Development emphasizes strand integrity, loading behavior, and delivery to follicular and epidermal compartments via intradermal or perifollicular routes, supported by our lipid nanoparticles for miRNA delivery services. | Inquiry |
| Skin-Targeted LNP for Cas9 mRNA and sgRNA | Designed for in situ genome-editing research in skin, where transient Cas9 expression, repeat dosing, and localized activity are key advantages over viral vectors. Route options include intradermal injection and transdermal topical application with reducible-lipid designs. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in 2D and 3D skin models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| Skin-Targeted LNP for ASO | Suitable for splice-modifying and knockdown oligonucleotide research in epidermal keratinocyte models, where nuclear delivery to skin cells remains a major bottleneck. Route options include intradermal administration and topical delivery with penetration-enhancing designs. Development focuses on oligonucleotide loading, uptake comparison across skin cell populations, and functional splice-correction readouts, supported by our lipid nanoparticles for ASO delivery services. | Inquiry |
| Skin-Targeted LNP for circRNA and saRNA | Designed for payloads requiring strong protection and sustained expression in skin-resident cells, such as long-duration growth-factor or matrix-protein expression in wound environments. Route options include intradermal injection and hydrogel- or microneedle-integrated formats. Development considers payload integrity, encapsulation behavior, and expression duration in skin cell models, supported by our lipid nanoparticles for circRNA delivery platform. | Inquiry |
| Skin-Targeted LNP for Protein and Peptide | Applicable to enzymes, growth factors, and signaling proteins intended for epidermal or dermal delivery research. Route options include topical application and intradermal administration. Formulation work emphasizes mild loading conditions, aggregation control, preserved biological activity, and release behavior in skin-mimicking media, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| Skin-Targeted LNP for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable actives studied in epidermal retention, anti-inflammatory, and dermocosmetic research contexts. Route options center on topical application, where particle size and occlusive behavior determine layer deposition. We evaluate drug–lipid compatibility, loading method, retention during surface modification, and release kinetics, supported by hydrophobic payload encapsulation in LNPs. | Inquiry |
| Skin-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to map penetration depth, layer-specific localization, follicular accumulation, and in vivo skin-versus-organ distribution trends across all administration routes, enabled by our tracking-labeled lipid nanoparticles capabilities. | Inquiry |
| Skin-Targeted LNP for Custom Payload | Developed for unusual payloads, co-delivery systems, or early feasibility studies in skin models. We evaluate payload compatibility, loading sequence, skin-targeting modification route, particle stability in the intended format, and delivery performance in the agreed skin cell and tissue models. | Inquiry |
Tell us your payload, target skin compartment, and preferred administration route, and BOC Sciences will propose a skin-targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as formulation and biological evidence becomes available.

We review the payload class, the intended skin compartment—viable epidermis, dermis, or follicular niche—the target cell population, the administration route, and the desired biological readouts. Model selection is defined at this stage: keratinocyte and fibroblast lines, primary cells from multiple donors, melanocyte models, 3D skin equivalents, and ex vivo skin for penetration studies. These inputs define the starting materials, comparators, and the screening plan.

We propose candidate ionizable lipids across defined pKa ranges, helper lipid and cholesterol balances, and surface architectures—PEG-stabilized, HA-decorated, or peptide- and antibody-displayed—then match the targeting layer to the target cell rather than defaulting to a fixed platform. Ratios are optimized through structured lipid ratio screening, and every targeted design is paired with a matched non-targeted control LNP so that selectivity claims rest on direct comparison.

Candidates are prepared under controlled mixing conditions and compared for particle size, PDI, zeta potential, ligand density, and payload retention against agreed thresholds. Critically for skin programs, we then stress-test the lead candidates in their intended format—dilution into gel vehicles, exposure to skin-surface pH ranges, shear during microneedle processing, and freeze–thaw or lyophilization cycles—and monitor stability throughout, supported by lipid nanoparticle stability studies. Only candidates that retain their attributes in the actual format advance.

Selected candidates are evaluated in skin cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression, knockdown, or editing. Ex vivo penetration studies in 3D equivalents and excised skin then map delivery depth and layer localization, and combined cellular and in vivo evaluation compares cutaneous delivery against hepatic and splenic accumulation using nanoparticle in vivo distribution analysis. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
A skin-targeted LNP may be well characterized chemically yet still fail to penetrate, transfect the wrong cell type, or lose performance the moment it enters a gel or a microneedle patch. We investigate formulation and biological factors together and use matched comparison studies to identify the step limiting performance.
The stratum corneum is a dense lipid–protein matrix that intact nanoparticles generally cannot cross, and very small particle sizes do not automatically solve the problem. We treat penetration as an engineering question with several parallel options: follicular routes where submicron particles accumulate preferentially around hair follicles, occlusion- and hydration-driven intercellular transport, charge-optimized surface designs, and device-assisted delivery through microneedle-created microchannels. Penetration depth is verified directly by ex vivo skin sectioning and imaging rather than assumed from particle size.
Primary keratinocytes and fibroblasts are among the harder cell types to transfect, performance varies between donors, and only a small fraction of internalized payload reaches the cytosol. We address this with ionizable lipid pKa tuning matched to epithelial cells, helper lipid adjustments, and formulation toxicity monitoring at working doses. When uptake is adequate but expression is not, LNP endosomal escape evaluation distinguishes trafficking limitations from formulation limitations before any reformulation is attempted.
Keratinocytes, fibroblasts, and melanocytes live millimeters apart yet respond to the same LNP very differently, so bulk skin expression data can hide a formulation that works only in one population. We quantify the cell-type composition of delivery using cell-marked uptake assays and payload-specific readouts, then adjust helper lipid identity, ligand display, and surface charge to shift the expression profile. When a formulation underperforms in one cell type, our LNP transfection troubleshooting services isolate whether the limiting step is binding, uptake, or intracellular release.
An LNP that is stable in buffer can aggregate, leak payload, or lose ligand exposure after dilution into a gel, contact with preservatives and surfactants, shear during microneedle molding, or lyophilization and rehydration. We evaluate candidate LNPs directly in their intended vehicle or format, screen excipient and cryoprotectant conditions that preserve particle attributes through drying and storage, and confirm that functional delivery survives the process—not just the size measurement.
Tell us about your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.
Skin-targeted LNPs create opportunities for nucleic acid and actives delivery across inherited skin disease research, wound repair, inflammatory skin conditions, and pigmentation biology. BOC Sciences supports customized LNP development for these applications, including payload selection, lipid and ligand engineering, formulation optimization, and functional delivery evaluation.
Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate skin-targeted LNPs tailored to your project.
We connect ionizable lipid pKa, helper lipid identity, and surface architecture to skin penetration depth and cell-type-selective expression, helping teams move beyond liver-tropic default formulations with a defined, data-supported design logic.

HA-lipid conjugates, cell-penetrating peptides, lectin ligands, and antibody fragments are designed, synthesized, and conjugated within one program, allowing the targeting layer to be matched to the skin cell population rather than forced onto a fixed platform.
Keratinocyte, fibroblast, melanocyte, and immune cell models, 3D skin equivalents, and ex vivo penetration studies are integrated into one evaluation chain, so that uptake claims are always checked against depth, layer localization, and functional payload expression.
Screening campaigns are organized around parallel candidate comparison with agreed particle thresholds, penetration depths, and functional readouts, giving teams fast, interpretable feedback on which design variable to adjust in the next iteration.
From ligand selection and lipid synthesis to formulation, vehicle and device-format stress testing, and skin-tissue evaluation, the full development chain is handled within one integrated plan, reducing the disconnect between targeting chemistry and skin-level performance.
Most intact LNPs do not cross an intact stratum corneum efficiently. The corneocyte lipid matrix admits particles in the low tens of nanometres, and penetration falls steeply as diameter grows, so practical access comes from perifollicular transport, hydration- or lipid-disrupted skin, or mechanical breaching with microneedles. In BOC Sciences skin-targeted LNP programs we quantify each route instead of assuming one: 60–80 nm and 110–130 nm batches are run side by side on ex vivo human or porcine skin in Franz cells, then reported as fluorescence depth profiles with receptor-cell co-localization. That evidence decides whether a topical gel, a follicle-directed lotion, or an intradermal format deserves investment for a given payload.
After intradermal injection, LNPs move with interstitial flow and are captured by the most abundant and most phagocytic cells of the dermis, which are fibroblasts and macrophages; keratinocytes sit behind the basement membrane and receive little of the dose. Correcting this means changing the particle, not the injection: shifting apparent pKa toward 7.0–7.4, replacing DOPE with DSPC, and raising the ionizable-to-helper lipid ratio have each biased expression toward the epidermis in published screens. We run parallel fibroblast and keratinocyte panels alongside matched non-targeted controls, so a shift in cell-type bias is measured directly rather than inferred from bulk tissue signal.
No single pKa is universal, but epidermal editing has repeatedly been favoured by ionizable lipids with apparent pKa in the 6.8–7.2 window, while the more acidic lipids typical of liver-tropic systems often underperform in keratinocytes. Headgroup chemistry and helper lipid identity matter just as much: an ALC-0315 core paired with DSPC has favoured keratinocytes, whereas the DOPE version of the same lipid favoured fibroblasts. Because pKa measured in buffer differs from pKa at the particle surface in skin interstitial fluid, we titrate candidates across a narrow 0.4-unit window and confirm the ranking functionally in primary cells instead of trusting the nominal value.
Melanocytes and follicle stem cells occupy compartments that systemically administered particles reach poorly, so targeting combines an anatomical route with a molecular handle. Follicle delivery treats the infundibulum as a reservoir, favouring particles below roughly 100 nm applied with massage or fractional laser pretreatment; melanocytes are then addressed through surface markers such as CD44, c-Kit or MC1R using hyaluronic acid, peptide or antibody conjugates. We synthesize the ligand in-house, hold conjugation density inside a defined range to avoid the uptake collapse seen at over-conjugation, and confirm cell identity by co-staining with Melan-A or tyrosinase rather than by reporter signal alone.
Functional delivery is best judged in tiers: two-dimensional monocultures for potency ranking, reconstructed human epidermis or full-thickness equivalents for barrier and spatial information, ex vivo skin for follicle and dermal access, and animal models only for the questions that remain open. Readouts should separate uptake from translation, because labelled lipid, labelled mRNA and expressed protein answer three different questions. Franz cell receptor-fluid analysis, confocal z-stack depth profiling, and cell-type-resolved flow cytometry after tissue dissociation together give a defensible picture, and every tier should carry a non-targeted comparator so that selectivity, not just signal intensity, is reported.